APO Research
Talk to an analyst

APO RESEARCH · REPORT

CXCR4 Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CXCR4 Antagonists Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchCXCR4 Antagonists Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal CXCR4 Antagonists Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal CXCR4 Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CXCR4 Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal CXCR4 Antagonists Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global CXCR4 Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CXCR4 Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CXCR4 Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CXCR4 Antagonists market include Sanofi, Merck, Roche, Eli Lilly, X4 Pharmaceuticals, Upsher-Smith Laboratories, Harmonic Pharma, GlycoMimetics and BioLineRx, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CXCR4 Antagonists market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CXCR4 Antagonists and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CXCR4 Antagonists revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CXCR4 Antagonists market.

CXCR4 Antagonists Segment by Company

Sanofi

Merck

Roche

Eli Lilly

X4 Pharmaceuticals

Upsher-Smith Laboratories

Harmonic Pharma

GlycoMimetics

BioLineRx

Biokine Therapeutics

CXCR4 Antagonists Segment by Type

USL311

Balixafortide (POL6326)

GMI-1359

BL-8040

Plerixafor (AMD3100)

Others

CXCR4 Antagonists Segment by Application

Chronic Inflammatory Diseases

HIV

Cancer

CXCR4 Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global CXCR4 Antagonists status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CXCR4 Antagonists key companies, revenue, market share, and recent developments.

3. To split the CXCR4 Antagonists breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CXCR4 Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CXCR4 Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze CXCR4 Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CXCR4 Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CXCR4 Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CXCR4 Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CXCR4 Antagonists industry.

Chapter 3: Detailed analysis of CXCR4 Antagonists company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CXCR4 Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CXCR4 Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CXCR4 Antagonists Industry Trends Table 2. CXCR4 Antagonists Industry Drivers Table 3. CXCR4 Antagonists Industry Opportunities and Challenges Table 4. CXCR4 Antagonists Industry Restraints Table 5. Global CXCR4 Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CXCR4 Antagonists Revenue Share by Company (2021-2026) Table 7. Global CXCR4 Antagonists Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CXCR4 Antagonists Key Company Manufacturing Base & Headquarters Table 9. Global CXCR4 Antagonists Company, Product Type & Application Table 10. Global CXCR4 Antagonists Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CXCR4 Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of USL311 Table 15. Significant Companies of Balixafortide (POL6326) Table 16. Significant Companies of GMI-1359 Table 17. Significant Companies of BL-8040 Table 18. Significant Companies of Plerixafor (AMD3100) Table 19. Significant Companies of Others Table 20. Global CXCR4 Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global CXCR4 Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global CXCR4 Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global CXCR4 Antagonists Sales Value Share by Type (2021-2026) Table 24. Global CXCR4 Antagonists Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Chronic Inflammatory Diseases Table 26. Significant Companies of HIV Table 27. Significant Companies of Cancer Table 28. Global CXCR4 Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global CXCR4 Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global CXCR4 Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global CXCR4 Antagonists Sales Value Share by Application (2021-2026) Table 32. Global CXCR4 Antagonists Sales Value Share by Application (2027-2032) Table 33. Global CXCR4 Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global CXCR4 Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global CXCR4 Antagonists Sales Value Share by Region (2021-2026) Table 36. Global CXCR4 Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global CXCR4 Antagonists Sales Value Share by Region (2027-2032) Table 38. Global CXCR4 Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global CXCR4 Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global CXCR4 Antagonists Sales Value Market Share by Country (2021-2026) Table 41. Global CXCR4 Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global CXCR4 Antagonists Sales Value Market Share by Country (2027-2032) Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sanofi CXCR4 Antagonists Product Portfolio Table 47. Sanofi Recent Development Table 48. Merck Company Information Table 49. Merck Business Overview Table 50. Merck CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Merck CXCR4 Antagonists Product Portfolio Table 52. Merck Recent Development Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Roche CXCR4 Antagonists Product Portfolio Table 57. Roche Recent Development Table 58. Eli Lilly Company Information Table 59. Eli Lilly Business Overview Table 60. Eli Lilly CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Eli Lilly CXCR4 Antagonists Product Portfolio Table 62. Eli Lilly Recent Development Table 63. X4 Pharmaceuticals Company Information Table 64. X4 Pharmaceuticals Business Overview Table 65. X4 Pharmaceuticals CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio Table 67. X4 Pharmaceuticals Recent Development Table 68. Upsher-Smith Laboratories Company Information Table 69. Upsher-Smith Laboratories Business Overview Table 70. Upsher-Smith Laboratories CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio Table 72. Upsher-Smith Laboratories Recent Development Table 73. Harmonic Pharma Company Information Table 74. Harmonic Pharma Business Overview Table 75. Harmonic Pharma CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Harmonic Pharma CXCR4 Antagonists Product Portfolio Table 77. Harmonic Pharma Recent Development Table 78. GlycoMimetics Company Information Table 79. GlycoMimetics Business Overview Table 80. GlycoMimetics CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GlycoMimetics CXCR4 Antagonists Product Portfolio Table 82. GlycoMimetics Recent Development Table 83. BioLineRx Company Information Table 84. BioLineRx Business Overview Table 85. BioLineRx CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. BioLineRx CXCR4 Antagonists Product Portfolio Table 87. BioLineRx Recent Development Table 88. Biokine Therapeutics Company Information Table 89. Biokine Therapeutics Business Overview Table 90. Biokine Therapeutics CXCR4 Antagonists Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Biokine Therapeutics CXCR4 Antagonists Product Portfolio Table 92. Biokine Therapeutics Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. CXCR4 Antagonists Product Image Figure 2. Global CXCR4 Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CXCR4 Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global CXCR4 Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. USL311 Image Figure 8. Balixafortide (POL6326) Image Figure 9. GMI-1359 Image Figure 10. BL-8040 Image Figure 11. Plerixafor (AMD3100) Image Figure 12. Others Image Figure 13. Global CXCR4 Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global CXCR4 Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global CXCR4 Antagonists Sales Value Share by Type (2021-2032) Figure 16. Chronic Inflammatory Diseases Image Figure 17. HIV Image Figure 18. Cancer Image Figure 19. Global CXCR4 Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global CXCR4 Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global CXCR4 Antagonists Sales Value Share by Application (2021-2032) Figure 22. Global CXCR4 Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global CXCR4 Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America CXCR4 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 25. North America CXCR4 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe CXCR4 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 27. Europe CXCR4 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific CXCR4 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific CXCR4 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America CXCR4 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 31. South America CXCR4 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa CXCR4 Antagonists Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa CXCR4 Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt CXCR4 Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • USL311
  • Balixafortide (POL6326)
  • GMI-1359
  • BL-8040
  • Plerixafor (AMD3100)
  • Others
Applications
  • Chronic Inflammatory Diseases
  • HIV
  • Cancer
Companies covered
  • Sanofi
  • Merck
  • Roche
  • Eli Lilly
  • X4 Pharmaceuticals
  • Upsher-Smith Laboratories
  • Harmonic Pharma
  • GlycoMimetics
  • BioLineRx
  • Biokine Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CXCR4 Antagonists Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CXCR4 Antagonists Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CXCR4 Antagonists Market Dynamics
  1. 2.1 CXCR4 Antagonists Industry Trends
  2. 2.2 CXCR4 Antagonists Industry Drivers
  3. 2.3 CXCR4 Antagonists Industry Opportunities and Challenges
  4. 2.4 CXCR4 Antagonists Industry Restraints
3 CXCR4 Antagonists Market by Company
  1. 3.1 Global CXCR4 Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global CXCR4 Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global CXCR4 Antagonists Company Ranking (2024-2026)
  4. 3.4 Global CXCR4 Antagonists Company Manufacturing Base and Headquarters
  5. 3.5 Global CXCR4 Antagonists Company Product Type and Application
  6. 3.6 Global CXCR4 Antagonists Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CXCR4 Antagonists Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CXCR4 Antagonists Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CXCR4 Antagonists Market by Type
  1. 4.1 CXCR4 Antagonists Type Introduction
  2. 4.1.1 USL311
  3. 4.1.2 Balixafortide (POL6326)
  4. 4.1.3 GMI-1359
  5. 4.1.4 BL-8040
  6. 4.1.5 Plerixafor (AMD3100)
  7. 4.1.6 Others
  8. 4.2 Global CXCR4 Antagonists Sales Value by Type
  9. 4.2.1 Global CXCR4 Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global CXCR4 Antagonists Sales Value by Type (2021-2032)
  11. 4.2.3 Global CXCR4 Antagonists Sales Value Share by Type (2021-2032)
5 CXCR4 Antagonists Market by Application
  1. 5.1 CXCR4 Antagonists Application Introduction
  2. 5.1.1 Chronic Inflammatory Diseases
  3. 5.1.2 HIV
  4. 5.1.3 Cancer
  5. 5.2 Global CXCR4 Antagonists Sales Value by Application
  6. 5.2.1 Global CXCR4 Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global CXCR4 Antagonists Sales Value by Application (2021-2032)
  8. 5.2.3 Global CXCR4 Antagonists Sales Value Share by Application (2021-2032)
6 CXCR4 Antagonists Regional Value Analysis
  1. 6.1 Global CXCR4 Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CXCR4 Antagonists Sales Value by Region (2021-2032)
  3. 6.2.1 Global CXCR4 Antagonists Sales Value by Region: 2021-2026
  4. 6.2.2 Global CXCR4 Antagonists Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CXCR4 Antagonists Sales Value (2021-2032)
  7. 6.3.2 North America CXCR4 Antagonists Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CXCR4 Antagonists Sales Value (2021-2032)
  10. 6.4.2 Europe CXCR4 Antagonists Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CXCR4 Antagonists Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CXCR4 Antagonists Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CXCR4 Antagonists Sales Value (2021-2032)
  16. 6.6.2 South America CXCR4 Antagonists Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CXCR4 Antagonists Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CXCR4 Antagonists Sales Value Share by Country, 2025 VS 2032
7 CXCR4 Antagonists Country-level Value Analysis
  1. 7.1 Global CXCR4 Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CXCR4 Antagonists Sales Value by Country (2021-2032)
  3. 7.2.1 Global CXCR4 Antagonists Sales Value by Country (2021-2026)
  4. 7.2.2 Global CXCR4 Antagonists Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CXCR4 Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CXCR4 Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CXCR4 Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi CXCR4 Antagonists Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck CXCR4 Antagonists Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche CXCR4 Antagonists Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Eli Lilly
  20. 8.4.1 Eli Lilly Company Information
  21. 8.4.2 Eli Lilly Business Overview
  22. 8.4.3 Eli Lilly CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly CXCR4 Antagonists Product Portfolio
  24. 8.4.5 Eli Lilly Recent Developments
  25. 8.5 X4 Pharmaceuticals
  26. 8.5.1 X4 Pharmaceuticals Company Information
  27. 8.5.2 X4 Pharmaceuticals Business Overview
  28. 8.5.3 X4 Pharmaceuticals CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  29. 8.5.4 X4 Pharmaceuticals CXCR4 Antagonists Product Portfolio
  30. 8.5.5 X4 Pharmaceuticals Recent Developments
  31. 8.6 Upsher-Smith Laboratories
  32. 8.6.1 Upsher-Smith Laboratories Company Information
  33. 8.6.2 Upsher-Smith Laboratories Business Overview
  34. 8.6.3 Upsher-Smith Laboratories CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Upsher-Smith Laboratories CXCR4 Antagonists Product Portfolio
  36. 8.6.5 Upsher-Smith Laboratories Recent Developments
  37. 8.7 Harmonic Pharma
  38. 8.7.1 Harmonic Pharma Company Information
  39. 8.7.2 Harmonic Pharma Business Overview
  40. 8.7.3 Harmonic Pharma CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Harmonic Pharma CXCR4 Antagonists Product Portfolio
  42. 8.7.5 Harmonic Pharma Recent Developments
  43. 8.8 GlycoMimetics
  44. 8.8.1 GlycoMimetics Company Information
  45. 8.8.2 GlycoMimetics Business Overview
  46. 8.8.3 GlycoMimetics CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlycoMimetics CXCR4 Antagonists Product Portfolio
  48. 8.8.5 GlycoMimetics Recent Developments
  49. 8.9 BioLineRx
  50. 8.9.1 BioLineRx Company Information
  51. 8.9.2 BioLineRx Business Overview
  52. 8.9.3 BioLineRx CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioLineRx CXCR4 Antagonists Product Portfolio
  54. 8.9.5 BioLineRx Recent Developments
  55. 8.10 Biokine Therapeutics
  56. 8.10.1 Biokine Therapeutics Company Information
  57. 8.10.2 Biokine Therapeutics Business Overview
  58. 8.10.3 Biokine Therapeutics CXCR4 Antagonists Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biokine Therapeutics CXCR4 Antagonists Product Portfolio
  60. 8.10.5 Biokine Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst